Patients Discontinuing Anti-Obesity Injections Gain Back Pounds Far More Rapidly Than People Using Diet and Exercise

Fresh analysis indicates that individuals who come off blockbuster slimming jabs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.

Published data in a major medical journal shows that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month upon discontinuation.

"Individuals purchasing these treatments should be informed of the potential of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.

That rate of recovery means a reversion to pre-treatment weight in about a year and a half.

Analyzing Therapies

The study, which looked at 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.

Researchers note that people who lose weight through dieting generally experience a more gradual creep back—perhaps 100 grams monthly—after stopping.

Understanding the Quick Regain

Doctors propose the way of the jabs is key to understanding the accelerated rebound.

GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.

"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating far more likely."

A Lifelong Issue?

Medical guidelines suggest the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.

Many experts argue that, due to the significant potential of weight regain, the therapy might need to be long-term.

This view is echoed by pharmaceutical companies, who say that the results "emphasize the long-term nature of obesity," comparing it to managing diseases like hypertension.

User Testimonies

Individuals who have stopped the medication report a sudden return of cravings.

"It felt as if a switch that goes on and you're instantly starving," recalled one woman.

This difficulty is worsened if patients have not adopted permanent lifestyle or habit changes during treatment.

Widespread Adoption

Recent estimates indicate that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.

• Adoption is greater among women compared to males.
• The middle-aged demographic shows the greatest level of interest.
• Many access the medications through private prescriptions rather than the NHS.

Ultimately, experts stress that while these medications are powerful tools for weight loss, they are not a standalone fix and lasting health benefits hinges on combined lifestyle management.